Navigation Links
News briefs from the October issue of Chest
Date:10/6/2009

VENTILATION MASK LEAKAGE MAY CONTAMINATE HOSPITAL ROOM

New research shows that certain noninvasive positive pressure ventilation (NPPV) masks may leak exhaled air up to a distance of 1 m from patients receiving treatments. This finding raises concerns about the potential spread of highly contagious respiratory illness within the hospital setting. Using a patient simulator that mimicked a patient with mild lung injury, researchers from Hong Kong measured the exhaled air leakage from two different face masks. Inspiratory pressure (IPAP) was gradually increased while expiratory pressure remained the same. Results showed that there was substantial exposure to exhaled air within a 1 m region of the patient receiving treatment. In addition, results showed that higher IPAP resulted in higher contamination. Researchers suggest that health-care workers take adequate precautions when providing NPPV support to patients with highly contagious or unknown respiratory conditions. This study is published in the October issue of CHEST, the peer-reviewed journal of the American College of Chest Physicians.

UNCONTROLLED ASTHMA PREVALENT AMONG MINORITY CHILDREN

African-American and Hispanic children have a high incidence of uncontrolled asthma, compared with Caucasian children with asthma. Using data from the National Asthma Survey, researchers from the Centers for Disease Control and Prevention assessed symptom control, medication use, and health-care utilization among 1,485 Caucasian (55 percent), African-American (20 percent) and Hispanic (25 percent) children with current asthma who reside in Alabama, California, Illinois, or Texas. The analysis showed that, compared with Caucasian children, African-American and Hispanic children had more indicators of poorly controlled asthma, including increased emergency health-care utilization, more daily rescue medication use, and less use of inhaled corticosteroids. The article is published in the October issue of CHEST, the peer-reviewed journal of the American College of Chest Physicians.

LABAs/ICS COMBINATION THERAPY MAY DO MORE HARM THAN GOOD

Current guidelines recommend the use of inhaled corticosteroids (ICS) in combination with long-acting beta agonists (LABAs) to reduce the frequency of exacerbations in symptomatic patients with severe to very severe chronic obstructive pulmonary disease (COPD). However, new research shows that this combination therapy may not provide significant benefits for patients and may cause adverse events. Researchers from Spain, Chile, and Uruguay reviewed 18 randomized controlled trials with 12,446 participants where the primary outcomes were COPD exacerbations and mortality. The analysis showed that therapy with LABAs/ICS did not decrease severe exacerbation or all-cause or respiratory mortality; however, moderate exacerbations were significantly reduced. Furthermore, the combination therapy was associated with an increased risk of pneumonia. This article is published in the October issue of CHEST, the peer-reviewed journal of the American College of Chest Physicians.


'/>"/>

Contact: Jennifer Stawarz
jstawarz@chestnet.org
847-498-8306
American College of Chest Physicians
Source:Eurekalert

Related medicine news :

1. News briefs from the journal Chest, August 2007
2. URAC Releases Issue Briefs Examining Stakeholders Views of Care Coordination Along the Healthcare Continuum
3. News briefs from the November issue of Chest
4. DuPont Group Vice President Briefs Investors on Performance Materials Segment
5. Nanotech Briefs Announces Call for Nominations for the Fourth Annual Nano 50(TM) Awards
6. News Briefs from Preventive Medicine 2008
7. Journal Chest -- March 2008 news briefs
8. News briefs: May issue of the journal Chest
9. Weill Cornell science briefs May 2008
10. News briefs from the American Society of Plastic Surgeons
11. News briefs from the American Society of Plastic Surgeons
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... New York, NY (PRWEB) , ... May 04, ... ... nation’s largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving ... patient services – is set to return to the esteemed Quaker Ridge Golf ...
(Date:5/4/2016)... York, NY (PRWEB) , ... May 04, 2016 ... ... leading private owners, developers and operators of commercial real estate proudly announced that ... 2015 Heart Health initiative. Team members portfolio-wide will continue Olshan Properties’ annual ...
(Date:5/4/2016)... ... May 04, 2016 , ... a2z, Inc. is ... and Canadian Association for Enterostomal Therapy (CAET) will be utilizing powerful and innovative ... to attendees and exhibitors for the 2016 WOCN Society & CAET Joint Conference—which ...
(Date:5/4/2016)... ... May 04, 2016 , ... All-Star ... created to assist the people of their local community. The agency pledges to ... community leaders. Their hope is to bring awareness to important local causes with ...
(Date:5/4/2016)... East Providence, Rhode Island (PRWEB) , ... May ... ... website was launched in April 2016. SS&A teamed up with one of the ... website. This legal information portal contains informative legal articles related to the law ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... Intec Pharma Ltd. (NASDAQ: NTEC ... the appointment of Pnina Strauss-Levy as Vice ... has 15 years of experience in clinical research and ... having supported the advancement of several products through the ... the United States and Europe ...
(Date:5/2/2016)... , May 2, 2016 Kalorama Information noted ... Medical Records) market in a recent white paper.  The ... Increased physician usage, a growing market are among the ... in Kalorama,s report EMR 2016: The Market ... Kalorama,s seventh complete study of the EMR industry, and ...
(Date:5/2/2016)... 2016  Celsion Corporation (NASDAQ: CLSN ), ... from the first cohort of patients in its ... Study) combining GEN-1, the Company,s DNA-based immunotherapy, with ... newly-diagnosed patients with advanced ovarian cancer who will ... In the first three patients dosed, GEN-1 plus ...
Breaking Medicine Technology: